Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs
Quiralte J, Delgado J, Sáenz de San Pedro B, et al. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2004;93: 360-364 (Pubitemid 39382977)
Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema
Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 2005; 95:154-158 (Pubitemid 41170176)
Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): A systematic structured review of the literature
DOI 10.1007/s00403-007-0757-6
Weberschock TB, Müller SM, Boehncke S, Boehncke WH. Tolerance to coxibs in patients with intolerance to non-steroidal anti-inflammatory drugs (NSAIDs): a systematic structured review of literature. Arch Dermatol Res 2007;299:169-175 (Pubitemid 46955882)